Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 3:2023:2701314.
doi: 10.1155/2023/2701314. eCollection 2023.

The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis

Wensheng Chen  1 , Huihua Chang  2 , Xiaoqi Wang  2 , Yuanping Wang  1   2 , Yuntao Liu  1 , Dawei Wang  1   2   3
Affiliations

The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis

Wensheng Chen et al. Evid Based Complement Alternat Med. .

Abstract

Background: Qiliqiangxin (QLQX) capsules are a commonly used proprietary Chinese medicine for the adjuvant treatment of chronic heart failure (CHF) in China. In recent years, several randomized controlled trials (RCTs) have reported on the efficacy and safety of QLQX combined with sacubitril/valsartan for CHF.

Objective: The purpose of this study was to systematically analyze the clinical efficacy and safety of QLQX combined with sacubitril/valsartan in the management of CHF and to provide clinicians as well as scientists with optimal evidence-based medical evidence.

Methods: We searched RCTs to evaluate the efficacy and safety of QLQX combined with sacubitril/valsartan in the treatment of CHF in the Wanfang Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, PubMed, Embase, and Cochrane Library databases from their inception until January 8, 2022. RCTs on QLQX in combination with sacubitril/valsartan for CHF were included. The outcome measures considered were total effective rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), 6-minute walking distance (6-MWD), and adverse events. The quality of the included RCTs was assessed thereafter using the Cochrane risk of bias tool. RevMan 5.3 software was used to conduct the meta-analysis.

Results: The meta-analysis included 17 trials involving 1427 CHF patients. The results indicated that with sacubitril/valsartan administration combined with QLQX treatment, the total effective rate (relative risk (RR) = 1.24; 95% confidence interval (CI) (1.17, 1.31); p < 0.01), LVEF (mean difference (MD) = 6.20; 95% CI (5.36, 7.05; p < 0.01)), and 6-MWD (MD = 55.87; 95% CI (40.66, 71.09); p < 0.01) of CHF patients were significantly increased, and the LVEDD value of CHF patients was noted to be significantly reduced (MD = -3.98; 95% CI (-4.47, -3.48); p < 0.01). Moreover, there was no increase in the number of adverse events during treatment (RR = 0.67; 95% CI (0.33, 1.34); p < 0.01).

Conclusions: This study indicated that in CHF patients, on the basis of sacubitril/valsartan treatment, combination with QLQX can potentially enhance the total effective rate, improve LVEF and 6-MWD, and reduce LVEDD values, with good safety. However, considering the poor quality of the included studies, a multicenter, randomized, double-blind controlled study is needed for further confirmation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Forest plot of total effective rate.
Figure 3
Figure 3
Forest plot of LVEF.
Figure 4
Figure 4
Forest plot of LVEDD.
Figure 5
Figure 5
Forest plot of 6-MWD.
Figure 6
Figure 6
Forest plot of adverse events.
Figure 7
Figure 7
Funnel plot of the (a) total effective rate, (b) 6-MWD, and (c) LVEF and Egger's test of the (d) total effective rate, (e) 6-MWD, and (f) LVEF.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Writing Group M., Mozaffarian D., Benjamin E. J., Go A. S., Arnett D. K., Blaha M. J. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation . 2016;133(4):e38–e360. doi: 10.1161/CIR.0000000000000350. - DOI - PubMed
    1. Groenewegen A., Rutten F. H., Mosterd A., Hoes A. W. Epidemiology of heart failure. European Journal of Heart Failure . 2020;22(8):1342–1356. doi: 10.1002/ejhf.1858. - DOI - PMC - PubMed
    1. Dunlay S. M., Roger V. L. Understanding the epidemic of heart failure: past, present, and future. Current Heart Failure Reports . 2014;11(4):404–415. doi: 10.1007/s11897-014-0220-x. - DOI - PMC - PubMed
    1. Heidenreich P. A., Albert N. M., Allen L. A., Bluemke D. A., Butler J., Fonarow G. C. Forecasting the impact of heart failure in the United States: a policy statement from the American heart association. Circ Heart Fail . 2013;6(3):606–619. doi: 10.1161/HHF.0b013e318291329a. - DOI - PMC - PubMed
    1. Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Saylan M., Sarangapani R. Pharmacokinetics and pharmacodynamics of Lcz696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (arni) The Journal of Clinical Pharmacology . 2010;50(4):401–414. doi: 10.1177/0091270009343932. - DOI - PubMed

LinkOut - more resources